EZH2 alters aggressive variant prostate cancer subtype evolution, but is not required for neuroendocrine prostate cancer
Jacobi, J. J.; Wadosky, K. M.; Jaiswal, N.; Zhang, X.; Wang, Y.; Singh, P.; Wang, J.; Gomez, E. C.; Wang, J.; Xu, B.; Cejas, P.; Kukreja, S.; LONG, H. W.; Goodrich, D. W.
Show abstract
Advanced prostate cancer (PrCa) remains a leading cause of cancer-related death among men because nearly all patients progress on standard therapy that targets androgen receptor (AR) signaling. An important mechanism driving therapeutic resistance is lineage plasticity, the ability of PrCa cells to reprogram into lineage variants like neuroendocrine (NE) PrCa that no longer depend on AR signaling. The histone methyltransferase EZH2 has been implicated in PrCa lineage plasticity and EZH2 inhibitors are being evaluated clinically for the treatment of PrCa. Here we test how Ezh2 impacts the evolution of PrCa lineage plasticity using genetically engineered mice and human patient data. Reduced Ezh2 expression diversifies the evolution of PrCa lineage variants, including a newly discovered variant with high expression of neurofilament genes, in both mice and humans. Lineage variant diversification is associated with activation of Klf transcription factor programs and AR cistrome reprogramming that is normally repressed by Ezh2. These findings advance the understanding of PrCa lineage plasticity and have implications for using EZH2 as a target for PrCa therapy.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Multiscale 3D Genome Reorganization during Skeletal Muscle Stem Cell Lineage Progression and Muscle Aging 95%
- L1 retrotransposons drive human neuronal transcriptome complexity and functional diversification 95%
- Cancer-associated DNA Hypermethylation of Polycomb Targets Requires DNMT3A Dual Recognition of Histone H2AK119 Ubiquitination and the Nucleosome Acidic Patch 95%
Similar papers in this journal
- Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer 97%
- Defining the cellular origin of seminoma by transcriptional and epigenetic mapping to the normal human germline 97%
- ECM-free patient-derived organoids preserve diverse prostate cancer lineages and uncover in vitro-enriched cell types 96%
Similar papers in this journal
- Cis-Regulatory Element Hijacking by Structural Variants Overshadows Higher-Order Topological Changes in Primary Prostate Cancer 97%
- EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genes 96%
- Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma 95%
Similar papers in this journal
- Defining cellular population dynamics at single cell resolution during prostate cancer progression 95%
- The CIC-ERF co-deletion underlies fusion independent activation of ETS family member, ETV1, to drive prostate cancer progression 95%
- Reorganization of postmitotic neuronal chromatin accessibility for maturation of serotonergic identity 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.